Shanghai Medicilon Inc. (SHA:688202)
89.34
-5.12 (-5.42%)
At close: Sep 11, 2026
Shanghai Medicilon Revenue
Shanghai Medicilon had revenue of 396.83M CNY in the quarter ending June 30, 2026, with 45.19% growth. This brings the company's revenue in the last twelve months to 1.38B, up 30.98% year-over-year. In the year 2025, Shanghai Medicilon had annual revenue of 1.16B with 12.08% growth.
Revenue (ttm)
1.38B
Revenue Growth
+30.98%
P/S Ratio
8.98
Revenue / Employee
552.77K
Employees
2,504
Market Cap
12.43B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.16B | 125.32M | 12.08% |
| Dec 31, 2024 | 1.04B | -327.89M | -24.01% |
| Dec 31, 2023 | 1.37B | -293.30M | -17.68% |
| Dec 31, 2022 | 1.66B | 491.67M | 42.12% |
| Dec 31, 2021 | 1.17B | 501.31M | 75.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Anhui Anke Biotechnology (Group) | 2.45B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.53B |
| Acrobiosystems | 950.35M |
| GemPharmatech | 878.13M |
| Mabwell (Shanghai) Bioscience | 873.99M |